Literature DB >> 22768468

Clinical and genetic study of 46 Italian patients with primary lymphedema.

S Michelini1, D Degiorgio, M Cestari, D Corda, M Ricci, M Cardone, A Mander, L Famoso, E Contini, R Serrani, L Pinelli, S Cecchin, M Bertelli.   

Abstract

Primary lymphedema is characterized by altered morphological development of lymphatic vessels causing fluid accumulation in interstitial spaces. In familial forms, it is primarily transmitted as a dominant Mendelian trait with heterozygous mutations in genes involved in lymphangiogenesis. We used PCR and direct sequencing to analyze the region of the fms-related tyrosine kinase 4 (FLT4) gene encoding the "tyrosine-kinase domain" and the single exon of the forkhead box C2 (FOXC2) gene in 46 Italian probands with primary lymphedema, 42 of whom had familial forms. We identified 12 mutations in 12 patients (12/46, 26%), six in the FLT4 gene and six in the FOXC2 gene. Most of the mutations (9/12, 75%) were new, and none were identified in 100 healthy subjects or listed in the NCBI dbSNP. A clear relation emerged between genotype and phenotype because 4/5 (80%) probands with onset at birth showed FLT4 mutations and 4/5 (80%) probands without distichiasis and with FOXC2 mutations had an amino-acid substitution outside the forkhead domain. Besides the allelic heterogeneity shown by unique mutations in each proband, the absence of mutations in almost 75% of familial cases of primary lymphedema also suggests genetic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22768468

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  7 in total

1.  Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways.

Authors:  Gabriele Bonetti; Stefano Paolacci; Michele Samaja; Paolo Enrico Maltese; Sandro Michelini; Serena Michelini; Silvia Michelini; Maurizio Ricci; Marina Cestari; Astrit Dautaj; Maria Chiara Medori; Matteo Bertelli
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

2.  Imbalance between Expression of FOXC2 and Its lncRNA in Lymphedema-Distichiasis Caused by Frameshift Mutations.

Authors:  Sara Missaglia; Daniela Tavian; Sandro Michelini; Paolo Enrico Maltese; Andrea Bonanomi; Matteo Bertelli
Journal:  Genes (Basel)       Date:  2021-04-27       Impact factor: 4.096

3.  FOXC2 disease-mutations identified in lymphedema-distichiasis patients cause both loss and gain of protein function.

Authors:  Daniela Tavian; Sara Missaglia; Paolo E Maltese; Sandro Michelini; Alessandro Fiorentino; Maurizio Ricci; Roberta Serrani; Michael A Walter; Matteo Bertelli
Journal:  Oncotarget       Date:  2016-08-23

4.  Favourable Changes in C-Peptide, C-Reactive Protein and Lipid Profile, and Improved Quality of Life in Patients with Abnormal Body Mass Index after the Use of Manual Lymphatic Drainage: A Case Series with Three-Month Follow-Up.

Authors:  Klaudia Antoniak; Katarzyna Zorena; Rita Hansdorfer-Korzon; Dagmara Wojtowicz; Marek Koziński
Journal:  Medicina (Kaunas)       Date:  2022-02-11       Impact factor: 2.430

5.  FOXC2 mutations in familial and sporadic spinal extradural arachnoid cyst.

Authors:  Yoji Ogura; Shoji Yabuki; Aritoshi Iida; Ikuyo Kou; Masahiro Nakajima; Hiroki Kano; Masaaki Shiina; Shinichi Kikuchi; Yoshiaki Toyama; Kazuhiro Ogata; Masaya Nakamura; Morio Matsumoto; Shiro Ikegawa
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

6.  Four generations of rare familial lymphedema (Milroy disease).

Authors:  Sankalp Gokhale; Sanjay Gokhale
Journal:  Med Princ Pract       Date:  2013-06-04       Impact factor: 1.927

7.  FOXC2 Disease Mutations Identified in Lymphedema Distichiasis Patients Impair Transcriptional Activity and Cell Proliferation.

Authors:  Daniela Tavian; Sara Missaglia; Sandro Michelini; Paolo Enrico Maltese; Elena Manara; Alvaro Mordente; Matteo Bertelli
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.